Cargando…

Recent advances in the development of breast cancer vaccines

The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC) cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high...

Descripción completa

Detalles Bibliográficos
Autores principales: Milani, Andrea, Sangiolo, Dario, Aglietta, Massimo, Valabrega, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204811/
https://www.ncbi.nlm.nih.gov/pubmed/25339848
http://dx.doi.org/10.2147/BCTT.S38428
_version_ 1782340603706605568
author Milani, Andrea
Sangiolo, Dario
Aglietta, Massimo
Valabrega, Giorgio
author_facet Milani, Andrea
Sangiolo, Dario
Aglietta, Massimo
Valabrega, Giorgio
author_sort Milani, Andrea
collection PubMed
description The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC) cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high specificity, and long-lasting efficacy due to the establishment of immunological memory. However, BC vaccines have failed to demonstrate meaningful results in clinical trials so far. This reflects the intrinsic difficulty in breaking the complex immune-escaping mechanisms developed by cancer cells. New vaccines should be able to elicit complex immunologic response involving multiple immune effectors such as cytotoxic and antibody-secreting B cells, innate immunity effectors, and memory cells. Moreover, especially in patients with large tumor burdens and metastatic disease, combining vaccines with other strategies, such as systemic BC therapies, passive immunotherapy, or immunomodulatory agents, could increase the effectiveness of each approach. Here, we review recent advances in BC vaccines, focusing on suitable targets and innovative strategies. We report results of most recent trials investigating active immunotherapy in BC and provide possible future perspectives in this field of research.
format Online
Article
Text
id pubmed-4204811
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42048112014-10-22 Recent advances in the development of breast cancer vaccines Milani, Andrea Sangiolo, Dario Aglietta, Massimo Valabrega, Giorgio Breast Cancer (Dove Med Press) Review The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC) cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high specificity, and long-lasting efficacy due to the establishment of immunological memory. However, BC vaccines have failed to demonstrate meaningful results in clinical trials so far. This reflects the intrinsic difficulty in breaking the complex immune-escaping mechanisms developed by cancer cells. New vaccines should be able to elicit complex immunologic response involving multiple immune effectors such as cytotoxic and antibody-secreting B cells, innate immunity effectors, and memory cells. Moreover, especially in patients with large tumor burdens and metastatic disease, combining vaccines with other strategies, such as systemic BC therapies, passive immunotherapy, or immunomodulatory agents, could increase the effectiveness of each approach. Here, we review recent advances in BC vaccines, focusing on suitable targets and innovative strategies. We report results of most recent trials investigating active immunotherapy in BC and provide possible future perspectives in this field of research. Dove Medical Press 2014-10-14 /pmc/articles/PMC4204811/ /pubmed/25339848 http://dx.doi.org/10.2147/BCTT.S38428 Text en © 2014 Milani et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Milani, Andrea
Sangiolo, Dario
Aglietta, Massimo
Valabrega, Giorgio
Recent advances in the development of breast cancer vaccines
title Recent advances in the development of breast cancer vaccines
title_full Recent advances in the development of breast cancer vaccines
title_fullStr Recent advances in the development of breast cancer vaccines
title_full_unstemmed Recent advances in the development of breast cancer vaccines
title_short Recent advances in the development of breast cancer vaccines
title_sort recent advances in the development of breast cancer vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204811/
https://www.ncbi.nlm.nih.gov/pubmed/25339848
http://dx.doi.org/10.2147/BCTT.S38428
work_keys_str_mv AT milaniandrea recentadvancesinthedevelopmentofbreastcancervaccines
AT sangiolodario recentadvancesinthedevelopmentofbreastcancervaccines
AT agliettamassimo recentadvancesinthedevelopmentofbreastcancervaccines
AT valabregagiorgio recentadvancesinthedevelopmentofbreastcancervaccines